Frontiers in Cardiovascular Medicine
JANUARY 25, 2024
Dyslipidemia is a leading contributor to atherosclerotic cardiovascular disease (ASCVD). We also present a single-center experience implementing a systematic inpatient protocol for lipid lowering therapy for secondary prevention of ASCVD.
Cardiovascular Diabetology
JULY 7, 2024
Objective Population-based national data on the trends in expenditures related to coexisting atherosclerotic cardiovascular diseases (ASCVD) and diabetes is scarce.
Circulation
NOVEMBER 11, 2024
Owing to improved management, the life expectancy of patients with hemophilia has increased significantly and predisposes them to risk of cardiovascular diseases and thrombotic events. The primary outcome was to estimate the prevalence of cardiovascular risk factors in patients with hemophilia compared to the general population.
Coronary Artery Disease Journal
MAY 26, 2024
Background Patients with cardiovascular disease (CVD) and risk factors have increased rates of adverse events and mortality after hospitalization for coronavirus disease 2019 (COVID-19). Methods The current study was a retrospective analysis of data from the US National (Nationwide) Inpatient Sample from 2020.
Frontiers in Cardiovascular Medicine
FEBRUARY 9, 2024
Aims The FLORIDA (Fractional FLOw Reserve In cardiovascular DiseAses) study sought to investigate outcomes of FFR-guided vs. angiography-guided treatment strategies in a large, real-world cohort. Eligible patients had at least one inpatient coronary angiogram for suspected coronary artery disease between January 2014 and December 2015.
Circulation
NOVEMBER 11, 2024
Background:Ischemic heart disease (IHD) is a prevalent cardiovascular disease (CVD) associated with high morbidity and mortality. Frailty and CVD are often interrelated, affecting disease and treatment outcomes. Circulation, Volume 150, Issue Suppl_1 , Page A4147397-A4147397, November 12, 2024.
Circulation
NOVEMBER 11, 2024
Background:Dietary magnesium (Mg+2) deficiency has been linked to hypertension, chronic kidney disease, and cardiovascular disease. vivostudies were performed on 9 hypertensive subjects enrolled in an acute inpatient protocol of salt loading (SL) (460mmoL/24 hrs) and salt depletion (SD) (10mmoL/24 hrs, and furosemide 40mg x 3).
Expert insights. Personalized for you.
69 
Let's personalize your content